Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000435 · ClinicalTrials.gov registry record · Phase 2
dnaJ Peptide for Relieving Rheumatoid Arthritis
A Phase 2 study, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00000435 is a Phase 2 study that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 160 participants.
The verdict
NCT00000435, a Phase 2 study, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
A small protein called dnaJ peptide may help people with rheumatoid arthritis (RA) by preventing their immune system cells from attacking their own tissues. The purpose of this study is to determine if small amounts of dnaJ peptide can "re-educate" immune cells in people with RA so that the cells stop attacking joint tissues.
Interventions
- DRUG dnaJ peptide
- DRUG None-placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 1999-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000435
The ClinicalTrials.gov registry entry for NCT00000435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dnaJ peptide is the first listed.
NCT00000435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000435 about?
NCT00000435 is a clinical study titled "dnaJ Peptide for Relieving Rheumatoid Arthritis". A small protein called dnaJ peptide may help people with rheumatoid arthritis (RA) by preventing their immune system cells from attacking their own tissues. The purpose of this study is to determine if small amounts of dnaJ peptide can "re-educate" immune cells in people with RA so that the cells st...
What is the current status of trial NCT00000435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 1999-09. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00000435?
The interventions under investigation include: dnaJ peptide (DRUG), None-placebo (DRUG).
Who is sponsoring clinical trial NCT00000435?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.